Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Comparing the Efficacy and Safety of Bimagrumab Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction (ACTIVATE-HFpEF)

NCT07920887 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07920887 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Comparing the Efficacy and Safety of Bimagrumab Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction (ACTIVATE-HFpEF)
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
November 30, 2029
Enrollment
540 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

diastolic heart failure, heart failure, diastolic, heart failure, normal ejection fraction, heart failure, preserved ejection fraction

Arms

As registered; 4 arms.

  • Bimagrumab Dose 1 ExperimentalBimagrumab

    Participants will receive bimagrumab subcutaneously (SC)

  • Bimagrumab Dose 2 ExperimentalBimagrumab

    Participants will receive bimagrumab SC

  • Placebo 1 Placebo comparatorPlacebo

    Participants will receive placebo SC

  • Placebo 2 Placebo comparatorPlacebo

    Participants will receive placebo SC

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Change from Baseline in the Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) Baseline, Week 52

Lead sponsor's other trials

Eli Lilly and Company, most recent start first.

Similar trials

Same condition (Heart Failure, Diastolic) and phase, most recent start first.